Drug
Dose 1 OF Bmn 331
Dose 1 OF Bmn 331: highest development phase Phase 1/2, developed by BioMarin Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- BioMarin Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dose 1 of BMN 331 NCT05121376 | Phase 1/2 | Hereditary Angioedema |
Latest
No recent events.
Follow Dose 1 OF Bmn 331 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.